Business Context and Reporting Period
This Form 8-K was filed by Pavmed Inc. on February 15, 2024, reporting events occurring on the same date. The company is incorporated in Delaware and trades on The Nasdaq Stock Market LLC under the symbols PAVM (Common Stock) and PAVMZ (Series Z Warrants).
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on a corporate action involving a special dividend and warrant adjustment.
Material Changes
- Special Dividend Distribution: The Company distributed 3,331,747 shares of its majority-owned subsidiary, Lucid Diagnostics Inc., to common and preferred stockholders. This represents approximately 6.9% of Lucid Diagnostics' outstanding common stock.
- Ownership Retention: Following the distribution, Pavmed Inc. retains approximately 65.2% ownership of Lucid Diagnostics.
- Warrant Adjustment: The exercise price of the Series Z Redeemable Warrants was reduced from $24.00 to $23.48 per share. This adjustment reflects a decrease of $0.52 per share, corresponding to the fair market value of the special dividend.
- Exclusions: The holder of the Company's senior convertible notes waived its right to participate in the distribution. Fractional shares were not distributed; entitlements were rounded to the nearest whole number.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on future operations, or specific risk factors beyond the mechanics of the distribution. The primary contingency noted is the waiver by the senior convertible notes holder regarding participation in the dividend.
Key Facts for Investor Verification
- Verify the current market price of Lucid Diagnostics shares to assess the value of the 0.37709668 shares received per Pavmed share held.
- Confirm the adjusted exercise price of $23.48 for Series Z Warrants in trading systems.
- Review the impact of the reduced ownership stake (from majority to 65.2%) on Pavmed's consolidated financial statements in future filings.
- Check if the waiver by the senior convertible notes holder impacts the company's debt covenants or liquidity position.